Pfizer (PFE)Sen. Alan Armstrong disclosed a sale $50K–$100K

$50,001–$100,000

Reported range · official band, not an exact amount

119 days

Disclosure lag

Traded

Mar 24, 2026

Disclosed

Jul 21, 2026

The story around this disclosure

Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.

1. Dec 31, 2025CongressDisclosed sale of PFE — reported range $100,001 - $250,000
2. Jan 23, 2026Federal contract · $22K obligatedDepartment of Defense awarded Pfizer: $22K obligated to date
3. Jan 26, 2026Federal contract · $9K obligatedDepartment of Defense awarded Pfizer: $9K obligated to date
4. Jan 29, 2026Federal contract · $3K obligatedDepartment of Defense awarded Pfizer: $2.8K obligated to date
5. Feb 3, 2026Company filing · Form 8-K · ResultsReported its results
6. Feb 9, 2026Government · Federal Register ruleAir Plan Approval; Connecticut; Revised Format for Materials Incorporated by Reference
7. Feb 10, 2026CongressDisclosed purchase of PFE — reported range $1,001 - $15,000
8. Feb 18, 2026Federal contract · $8K obligatedDepartment of Defense awarded Pfizer: $8.2K obligated to date
9. Feb 19, 2026Government · Federal Register noticeGranting of Requests for Early Termination of the Waiting Period Under the Premerger Notification Rules
10. Feb 24, 2026FDAFDA drug approval: Braftovi
11. Feb 24, 2026FDAFDA drug approval: Braftovi
12. Feb 26, 2026Government · Federal Register noticeDetermination of Regulatory Review Period for Purposes of Patent Extension; ORLYNVAH
13. Mar 6, 2026FDAFDA drug approval: Xeljanz
14. Mar 6, 2026FDAFDA drug approval: Xeljanz XR
15. Mar 9, 2026Government · Federal Register noticeAspen Global Inc. c/o Lachman Consultant Services, Inc., et al.; Withdrawal of Approval of 46 New Drug Applications
16. Mar 13, 2026CongressDisclosed partial sale of PFE — reported range $1,001 - $15,000
17. Mar 24, 2026 · this disclosureCongressDisclosed sale of PFE — reported range $50,001 - $100,000

What came next

1. Mar 27, 20265% stakeThe Vanguard Group reported a passive stake (13G)
2. Apr 3, 2026Government · Federal Register noticeDetermination of Regulatory Review Period for Purposes of Patent Extension; HYMPAVZI
3. Apr 8, 2026Federal contract · $15K obligatedDepartment of Defense awarded Pfizer: $15K obligated to date
4. Apr 23, 2026Federal contract · $2K obligatedDepartment of Defense awarded Pfizer: $2.2K obligated to date
5. Apr 23, 2026Federal contract · $23K obligatedDepartment of Defense awarded Pfizer: $23K obligated to date
6. May 1, 20265% stakeVanguard Capital Management reported a passive stake (13G) of 7.5%
7. May 5, 2026Company filing · Form 8-K · ResultsReported its results
8. May 13, 2026Federal contract · $25K obligatedDepartment of Defense awarded Pfizer: $25K obligated to date
9. May 15, 2026Federal contract · $543K obligatedDepartment of Health and Human Services awarded Pfizer: $543K obligated to date
10. May 20, 2026Federal contract · $2K obligatedDepartment of Defense awarded Pfizer: $2.2K obligated to date
11. Jun 5, 2026FDAFDA drug approval: Hympavzi
12. Jun 8, 2026Government · Federal Register noticeDetermination That Protamine Sulfate (Protamine Sulfate) Intravenous; Solution, 50 Milligrams/5 Milliliters, and Other Drug Products Were Not Withdrawn From Sale for Reasons of Safety or Effectiveness
13. Jun 8, 2026CongressDisclosed sale of PFE — reported range $15,001 - $50,000
14. Jun 9, 2026InsiderOfficer sold ~$51K of PFE shares in the open market
15. Jun 18, 2026Company filing · Form 8-K · Executive changeChanged a top executive or board member“On June 16, 2026, Dave Denton notified Pfizer Inc. (the “Company”) that he will step down from his current position as Chief Financial Officer effective August 15, 2026 for a professional opportunity outside of the pharmaceutical industry in consumer goods, and that his departure is not related to the Company’s financial or operating results or to any disagreements with the Company regarding the Company’s financial,…”
16. Jun 24, 2026FDAFDA drug approval: Ibrance
17. Jun 24, 2026FDAFDA drug approval: Ibrance
18. Jul 6, 2026Government · Federal Register noticeEndo Operations Limited, et al.; Withdrawal of Approval of 34 New Drug Applications
19. Jul 20, 2026Government · Federal Register noticeForeign-Trade Zone (FTZ) 43, Notification of Proposed Production Activity; Pfizer Inc.; (Pharmaceutical Products); Kalamazoo and Portage, Michigan

How to read Senate eFD periodic transaction report

The STOCK Act is a 2012 US law that requires members of Congress, and some senior staff, to publicly report their stock trades, and those of their spouse and dependent children, within 45 days.

Full guide: What is the STOCK Act?

What else is on file for Pfizer

For Pfizer, OQRO holds 4 insider filings (SEC Form 4 or Form 144), 4 Congress trade reports and 54 fund holdings reports (13F) dated in the last 90 days.

These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its PFE page.

Other recent filings by Sen. Alan Armstrong

• Senate eFD periodic transaction report at Williams Companies (WMB)Sep 17, 2026
• Senate eFD periodic transaction report at Williams Companies (WMB)Sep 17, 2026
• Senate eFD periodic transaction report at KKR & Co. (KKR)Jul 21, 2026
• Senate eFD periodic transaction report at Globe Life (GL)Jul 21, 2026
• Senate eFD periodic transaction report at Copart (CPRT)Jul 21, 2026

The full history of Sen. Alan Armstrong is on the profile page.

How this filing works

• The STOCK Act

Other disclosures at Pfizer

• SEC Form 13F-HRAug 14, 2026
• SEC Form 13F-HRAug 14, 2026
• SEC Form 13F-HRAug 14, 2026
• SEC Form 13F-HRAug 14, 2026
• SEC Form 13F-HRAug 14, 2026
• SEC Form 13F-HRAug 14, 2026

Everything OQRO holds on this company is on its PFE page.